bioRxiv Science⌕ Search

Biology subjects

Rangel-Barajas, C.

Publications and source records attributed to Rangel-Barajas, C..

2 recordsLinked to original sources

Dorsomedial Striatum Calcium Permeable AMPA Receptors in the Development of Aversion-Resistant Alcohol Drinking

RationaleAlcohol use disorder is defined by drinking alcohol despite knowledge of negative consequences, often referred to as aversion-resistant drinking (ARD). The dorsomedial (DMS) and dorsolateral striatum (DLS) are necessary for goal-directed and habitual action selection, respectively. Leading hypotheses posit that once drug use becomes compulsive, DMS dependence degrades while DLS dependence increases. This shift may be mediated by changes in synaptic weights from glutamatergic inputs. ObjectivesUsing a combination of western-blot, micro-injections, and ex-vivo electrophysiology, we investigated the role of -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors AMPAR, which drive glutamatergic transmission, during quinine-adulterated alcohol (QuA) drinking in the DMS and DLS across the development of ARD. ResultsWe found that AMPAR subunit composition and function change in the DMS across the development of ARD whereby, calcium permeable (CP) - AMPARs drive behavior. Western blots revealed a negative relationship between DMS GluA1 and QuA drinking in aversion-sensitive mice and positive relationships between DMS or DLS GluA1/A2 ratios and QuA drinking in ARD mice. DMS CP-AMPAR antagonism caused an increase in QuA drinking suggesting that CP-AMPARs in the DMS prevent ARD. Ex-vivo electrophysiology of DMS spiny projection neurons (SPNs) revealed that ARD mice had a greater rectification index than aversion-sensitive mice indicating that SPNs in the DMS express more CP-AMPARs following the development of ARD. ConclusionsThese data provide evidence that repeated alcohol binges alter DMS CP-AMPAR activity, where initial DMS activity acts to prevent ARD but after repeated binges that result in ARD, DMS SPNs recruit CP-AMPARs.

neuroscience↗

Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease Models

Src homology 2 domain-containing inositol 5-phosphatase 1 (SHIP1), encoded by the gene INPP5D, is a lipid phosphatase that negatively regulates immune receptor signaling in hematopoietic cells and microglia. Here, we describe a pyridyl-pyrazole-piperidine scaffold and the lead compound 3-((2-chlorobenzyl)oxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridine (32), which demonstrates SHIP1 target engagement, brain exposure, and evidence of a central pharmacodynamic response in vivo. Structure-activity relationship studies, guided by biochemical and cellular assays using multiple human and murine protein constructs and cells, identified SHIP1-active ligands. A thermal shift assay using full-length SHIP1 was used to assess compounds for cellular target engagement, while studies in IL-4 conditioned THP-1 cells was used to demonstrate changes in downstream AKT signaling. Targeted lipidomics revealed changes in the overall phosphoinositide pool consistent with SHIP1 target engagement and reduction of phospho-AKT levels. In a protein-lipid overlay assay, compound 32 induced changes in the relative association of SHIP1 with multiple phosphatidylinositols on a membrane surface. In high-content cellular imaging assays, compound 32 enhanced the uptake of myelin/membrane debris and fibrillar amyloid by primary murine microglia, phenocopying a genetic model with reduced SHIP1 expression. Finally, oral administration of compound 32 resulted in brain exposure sufficient to alter gene expression and reduce IL-1{beta} levels as pharmacodynamic markers of microglial activation and neuroinflammation in an amyloidosis mouse model of Alzheimers disease. Collectively, these results define a scaffold with SHIP1 target engagement, CNS exposure, and in vivo activity, providing a foundation for the optimization of brain-penetrant SHIP1 ligands suitable for further mechanistic studies and therapeutic development for the treatment of Alzheimers disease.

pharmacology and toxicology↗